INTRODUCTION: Ethnic differences in the relationship of BMI to morbidity and mortality have led investigators to question whether a single cutpoint for obesity should be applied to all groups. Comparisons across ethnic groups have used a variety of disease outcomes and measures of effect. METHODS: Data were from 45 ± 64 year old women in the Atherosclerosis in Communities (ARIC) study. All outcomes were examined prospectively and included diabetes (757 cases), hypertension (1,518 cases) and low levels of high-density lipoprotein (HDL) (2,281 cases). Incidence rates were calculated using Poisson regression and adjusted for age, educational level, physical activity, alcohol consumption, smoking and study center. Rate ratios and rate differences were calculated using the adjusted incidence rates and a BMI of 21 as the reference. RESULTS: The incidence of all 3 conditions increased signi®cantly with increasing BMI among women in both ethnic groups. Among white women with a BMI of 30 the incidence of diabetes was 26 casesa1000 person-years, the risk difference was 21 casesa1000 person-years and the rate ratio was 4.9. Similar levels of risk for African American women were 32, 23 and 3.3 respectively. For hypertension the same 3 risk estimates were 50, 23, and 1.8 in white women; and 118, 36 and 1.4 in African American women. For low HDL the estimates were 54, 13, and 1.3 in white women; and 34, 6 and 1.2 in African American women. CONCLUSIONS: Elevations in BMI were associated with increased risk of developing diabetes, hypertension and low HDL in both African American and white women. The use of different risk estimates and different outcomes can strongly impact comparisons of the effect of BMI across ethnic groups.
INTRODUCTION: Ethnic differences in the relationship of BMI to morbidity and mortality have led investigators to question whether a single cutpoint for obesity should be applied to all groups. Comparisons across ethnic groups have used a variety of disease outcomes and measures of effect. METHODS: Data were from 45 ± 64 year old women in the Atherosclerosis in Communities (ARIC) study. All outcomes were examined prospectively and included diabetes (757 cases), hypertension (1,518 cases) and low levels of high-density lipoprotein (HDL) (2,281 cases). Incidence rates were calculated using Poisson regression and adjusted for age, educational level, physical activity, alcohol consumption, smoking and study center. Rate ratios and rate differences were calculated using the adjusted incidence rates and a BMI of 21 as the reference. RESULTS: The incidence of all 3 conditions increased signi®cantly with increasing BMI among women in both ethnic groups. Among white women with a BMI of 30 the incidence of diabetes was 26 casesa1000 person-years, the risk difference was 21 casesa1000 person-years and the rate ratio was 4.9. Similar levels of risk for African American women were 32, 23 and 3.3 respectively. For hypertension the same 3 risk estimates were 50, 23, and 1.8 in white women; and 118, 36 and 1.4 in African American women. For low HDL the estimates were 54, 13, and 1.3 in white women; and 34, 6 and 1.2 in African American women. CONCLUSIONS: Elevations in BMI were associated with increased risk of developing diabetes, hypertension and low HDL in both African American and white women. The use of different risk estimates and different outcomes can strongly impact comparisons of the effect of BMI across ethnic groups.
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Obesity further deteriorates glucose metabolism in women with prior gestational diabetes 
INTRODUCTION:
Gestational diabetes mellitus (GDM) often precedes type-2 diabetes. It is therefore important to study glucose tolerance by monitoring insulin sensitivity and insulin secretion in women with a history of GDM. Aim of this study was the evaluation of the impact of obesity on glucose metabolism in former GDM. METHODS: A total of 60 women were analysed, divided into two groups according to BMI b 27.5 (Obese, OB, N 28, BMI 31.4 AE 0.8 kgam 2 , basal glucose Gb 98.9 AE 3.1 mgadl, basal insulin Ib 12.2 AE 1.6 mUaml; basal Cpeptide CPb 313.5 AE 55.2 ngadl, basal proinsulin Pb 16.1 AE 4.9 pmolal; NonObese, NO, N 32, BMI 23.7 AE 0.4, Gb 85.9 AE 1.1, Ib 7.1 AE 0.7, CPb 161.6 AE 10.8, Pb 4.6 AE 0.8, p`0.02). Subjects underwent a 75-g oral glucose tolerance test with frequent sampling for 3 h. Glucose, insulin, C-peptide and proinsulin concentrations were measured and analysed with mathematical modeling for insulin sensitivity (OGIS) and for insulin and proinsulin B-cell secretion. Liver and systemic kinetics of these hormones were also obtained, allowing segregation of the basal and stimulated components. RESULTS: Glucose and insulin levels (area under the curve, AUC) were higher in OB (glucose AUC: 1.42 AE 0.07 mola1.3 h vs 1.14 AE 0.04, p 0.0006; insulin AUC: 65.7 AE 7.1 nmola1.3 h vs 44.9 AE 4.5, p 0.015). OGIS showed an impaired insulin action (OB: 393 AE 15 ml min 71 m 72 , NO: 448 AE 12, p 0.006). Total insulin and proinsulin secretion was higher in OB than in NO (TIS 35.2 AE 4.6 nmola1.3 h vs 24.3 AE 1.7; TPS 0.24 AE 0.03 vs 0.15 AE 0.02, p`0.02). This was mostly due to an increased basal secretion (insulin OB: 65.2 AE 11.6 pmolalamin, NO: 31.5 AE 2.1; proinsulin OB: 0.42 AE 0.06, NO: 0.20 AE 0.03, p`0.004), while the component stimulated by hyperglicemia did not change (insulin OB: 23.5 AE 2.8 nmola1.3 h, NO: 18.6 AE 1.4; proinsulin OB: 0.17 AE 0.02, NO: 0.12 AE 0.02, p b 0.08). CONCLUSION: Obesity in former GDM women further deteriorates glucose metabolism without affecting hepatic insulin extraction, insulinaproinsulin cosecretion factor and peptides' clearances. Despite increased total insulin and proinsulin secretion, the B-cell is unable to compensate for the marked insulin resistance and prevailing hyperglycemia (given the unchanged dynamic secretion), indicating B-cell impairment in obese women at risk for type-2 diabetes.
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Impaired plasma free fatty acid utilization in men at risk for type 2 diabetes mellitus ). The Acetate Recovery Factor was determined to correct plasma FFA oxidation. RESULTS: No differences in total fat and carbohydrate oxidation (expressed per kg FFM) were found between groups. Rate of appearance (Ra) and plasma FFA oxidation were lower in subjects with IGT and DM as compared to obese controls, during rest and exercise. Triglyceride-derived FA oxidation (i.e. muscle triglyceride) was higher during exercise in IGT and DM ( OB 17.0 AE 2.0 27.4 AE 2.0 6.9 AE 1.0 19.6 AE 1.5 72.0 AE 1.3 74.0 AE 2.0 IGT 10.6 AE 0.9 19.3 AE 1.8 3.7 AE 0.3 15.0 AE 1.7 70.5 AE 0.3 3.6 AE 1.4 DM 12.7 AE 1.2 20.0 AE 2.4 4.4 AE 0.6 14.1 AE 1.9 70.2 AE 0.6 1.4 AE 1.4 p`0.05 p`0.05 p`0.01 p`0.07 p`0.05
M Mensink
This study demonstrates that disturbances in plasma FFA utilization are already present in prediabetic men (IGT). This suggest that disturbances in (skeletal muscle) fatty acid metabolism are of importance in the development of type 2 diabetes mellitus.
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Is serum insulin-like growth factor binding protein (IGFBP)-1 a measure for hepatic insulin resistance?
T Wasada 1 , C Takahashi correlation to lean body mass (r 0.63, p`0.0001; Natali A et al. Diabetologia 43:1266 Diabetologia 43: , 2000 and hepatic insulin resistance to the HOMA-IR (r 0.69, p`0.0001; Matsuda M et al. Diabetes Care 22: 1462 , 1999 . Since hepatic insulin resistance is expressed as the product of EGO by fasting serum insulin, we believe that basal serum IGFBP-1 concentration or its suppression by insulin (nIGFBP-1anIRI) may be an alternative measure for hepatic insulin resistance. However, validation of these results is still required.
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Effects of diet fat and endurance training on insulin receptor tyrosine protein kinase in dietary obese rats Dept. of Human Sport Science, Beijing Physical Education University, Beijing, 100084, China OBJECTIVE: To clarify the change in activity of insulin receptor tyrosine protein kinase (TPK) in dietary obese rats and to study the mechanism of endurance training (ET) on reducing body fat and the effects of dietary fat level on TPK in obese rats. METHODS: Dietary induced obese male SD rats (DIO) were taken by feeding high fat diet (HF) (En%: prot. 20.0%, fat 51.7%, CHO 29.3%) for 10 weeks, and randomly divided into 3 groups: endurance training with high fat diet (ET-HF) (treadmill: 65 ± 75% Vo2max), endurance training with normal fat diet(ET-NF), and normal fat diet (NF) (En%: prot. 20.0%, Fat 19.1%, CHO 61.3%). All rats were treated for another 8 weeks. Two control groups were fed for 18 weeks, either in high fat diet (C-HF, DIO) or normal fat diet (C-NF). Plasma insulin, insulin receptor binding and TPK activity were measured in hepatocytes membranes (HM) and myocytes membranes (MM). RESULTS: Compared to C-NF, C-HF rats were hyperinsulinemia (35.2 AE 4.5 vs 26.9 AE 6.1 mUaml, P`0.0l), the insulin receptor binding was reduced signi®-cantly in HM (7.8 AE 0.1 vs 13.7 AE 0.5 BaT%, P`0.001) and MM (soleus: 5.0 AE 0.1 vs 3.6 AE 0.3 BaT%, P`0.01; tibialis: 4.9 AE 0.1 vs 3.4 AE 0.3 BaT%, P`0.01), and the TPK activity was also reduced in HM (5.2 AE 0.3 vs 6.0 AE 0.4 cpmÁ1000amg protÁmin, P`0.05_and MM (soleus: 2.8 AE 0.1 vs 3.7 AE 0.2 cpmÁ1000amg protÁmin, P`0.001; tibialis: 2.6 AE 0.1 vs 3.2 AE 0.2 cpmÁ 1000amg protÁmin, P`0.05). In ET-HF body fat content was reduced compared to C-HF (33.5 AE 4.2 vs 43.0 AE 4.6 gal00 g dry wt, P`0.01) and abate hyperinsulinemia (35.2 AE 4.5 vs 30.6 AE 9.7 mUaml) by enhancing insulin receptor binding (HM: 10.7 AE 0.2 vs 7.8 AE 0.1 BaT%, P`0.001). In NFTPK activity was raised compared to C-HF in HM (6.2 AE 0.3 vs 5.2 AE 0.3 cpmÁ1000amg protÁmin, P`0.01). In the ET-NF group body fat content was decreased to the same level as that in the C-NF group. CONCLUSION: Hyperinsulinemia and insulin resistance are responsible for obesity in high fat diet. Endurance training and lower diet fat reduced the level of body fatness and attenuated insulin resistant by increasing insulin receptor binding and TPK activity.
Wang Congrong
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Prevalence of obesity and its co-morbidities in Chinese in Shanghai, China 2 ) 4.0%, DM 9.2% and hypertension 35.4%. After age and sex strati®cation, prevalence of overweight and obesity was 22.9% and 2.4% in men, and 14.2% and 4.2% in women aged less than 40 years, while 31.4% and 2.2% in men, and 35.6% and 5.6% in women aged over 40 years. The odds ratio of DM, hypertension signi®cantly rose with BMI increasing (P`0.001). In BMI 23.0 ± 24.9 kgam 2 group, the risk of DM, hypertension increased 2 times than that of BMI 18.5 ± 22.9 kgam 2 group (P`0.001). CONCLUSION: It was demonstrated that one third of Chinese aged over 15 years were identi®ed to be overweight in Shanghai, China. The optimal BMI cutoff point to predict type 2 DM and hypertension should be 23 kgam 2 in Chinese.
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BMI, waist circumference and waist to hip ratio as predictors of diabetes in a community-based cohort 
INTRODUCTION:
To evaluate the ability of BMI, waist circumference, waist to hip ratio, and combinations of these variables to discriminate individuals who develop type 2 diabetes. METHODS: Data were from 45 ± 64 year old men and women who were members of the Atherosclerosis Risk in Communities (ARIC) cohort. The analysis sample consisted of 12,814 African American and white participants who were free of diabetes at baseline. Participants were re-examined at 3-year intervals on 3 occasions. Weight, height, waist circumference and hip circumferences were measured at the baseline examination (1987 ± 1990) . Diabetic status was measured at each exam (de®ned as one glucose b 7.0 mmolal after fasting for at least 8 hours, one non-fasting glucose b 11.1 mmolal, self-report of physician diagnosis of diabetes or report of taking medication for diabetes). RESULTS: 1,515 new cases of diabetes were identi®ed over the 9-year followup. Areas under receiver operating characteristic (ROC) curves ranged from 0.66 to 0.73 for each of the 3 anthropometric variables. The curves were smooth with no indication of a threshold. Waist tended to have the highest ROC statistic in all groups, but differences were small. Use of two anthropometric variables in combination did not produce large gains above levels obtained with the single measures. ROC statistics tended to be higher in whites than in African Americans. CONCLUSION: The three anthropometric indices tested were approximately equivalent in their ability to predict diabetes.
P212
Effects of a weight maintenance program with or without exercise training on the occurrence of the metabolic syndrome in obese men Successful weight maintenance (WM) after weight reduction (WR) is a major challenge in obesity treatment. Our aim was to study whether adding walking or strength training to dietary counselling after WR improves WM and decreases the occurence of the metabolic syndrome (MBO) in obese, nonsmoking, nonmedicated men. 90 men with BMI range 30 ± 40 (mean 33.0, SD 2.6) and a waistline b 100 cm were accepted. After VLED for 2 months (mo.) they were randomized into 3 WM intervention groups (walking, strength training, diet) for 6 mo. Excercise groups trained 3Â45 minawk. All groups received similar dietary advice. After 8-mo. intervention there was a 23-mo. follow-up. Measurements were carried out at 0, 2, 8, 20 and 31 mo. from beginning (n 82 at 8 mo., 66 at 31 mo.).
After 2 mo. the mean weight loss was 14.2 (4.0) kg. Compared to the start, body composition (underwater weighing), fasting serum lipids, and insulin and glucose during OGTT were improved similarly in the 3 groups after WM (8 mo. There were no clear differences in weight and coronary risk factors at the end of the study between the WM intervention groups. This might be partly due to poor adherence to excercise training. However, clustering of risk factors, i.e. MBO, seemed to be favourably affected by the WM program. Our results imply that excercise training alone is not the solution to improved WM but dietary counselling is also needed. Because of the known positive health effects of physical activity, regardless of weight change, there is an urgent need to study methods to improve excercise adherence in obese patients.
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Relationship between serum fatty acids and insulin sensitivity in obese children In contrast, values of the principal n-6 and n-3 long-chain polyunsaturated fatty acids (PUFAs), arachidonic acid (C20:4n-6) and docosahexaenoic acid (C22:6n-3) as well as the sum of n-6 and n-3 PUFAs were signi®cantly and inversely related to OGTT BI concentrations in TG and TOT (table) . Similarly, signi®cant and inverse correlations were seen between n-6 PUFA values and PI concentrations (r 7 0.50, p`0.05) and AC values (r 7 0.49, p`0.05) in TOT. The productasubstrate ratios for the d-5 desaturase enzyme (C20: 4n-6aC20:3n-6) were signi®cantly and inversely related to BI concentrations in TG, PL and TOT (Table) . 
Two important functions of human adipose tissue are the stroagearelease of fatty acids and the secretion of proteins e.g. leptin and tumor necrosis factor-a (TNF-a). Site speci®c differences in lipolysis and protein secretion have been demonstrated previously in adipocytes. In the current study, site speci®c differences in lipolysis and leptin and TNF-a secretion were investigated between human omental and subcutaneous preadipocytes. METHODS: Preadipocytes from obese but otherwise healthy patients were isolated and differentiated in the presence or absence of the PPAR-g agonist, rosiglitazone. Lipolysis was estimated by measurement of glycerol release, adipose leptin and TNF-a secretion by a respective human ELISA method., mRNA levels were measured by solution hybridization technique. RESULTS: After 16 days of incubation in the presence or absence of rosiglitazone, leptin secretion and leptin mRNA levels were found to be higher in subcutaneous as compared to omental preadipocytes (p`0.05). In contrast, TNF-a secretion and mRNA levels as well as basal and norepinephrine-induced lipolysis did not differ between subcutaneous and omental preadipocytes. Rosiglitazone stimulated preadipocyte differentiation and increased catecholamine-induced lipolysis in the cells from both adipose tissue depots. However, rosiglitazone reduced preadipocyte mRNA levels and secretion of both leptin and TNF-a. CONCLUSION: There seems to be regional differences in leptin secretion but not in lipolysis or TNF-a secretion in preadipocytes at a low and high level of differentiation. The regional variation in leptin secretion may be determined by intrinsic factors of (pre-)adipocytes. Conversely, site variations previously shown in adipocyte lipolysis may be governed by external factors.
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In normal men, free fatty acids reduce peripheral, but not splanchnic glucose uptake
V Rigalleau
INTRODUCTION: Raising plasma FFA levels reduces muscle glucose uptake, but their effect on splanchnic glucose uptake, total glucose output and glucose cycling may also be critical to produce lipid-induced glucose intolerance.
METHODS:
In eight normal volunteers, we measured glucose turnover and cycling rates ([ 2 H 7 ] glucose infusion) during a moderately hyperglycemic (7.7 mmolaL) hyperinsulinemic clamp, before and after ingestion of a dideuterated oral glucose load (700 mgakg). Each test was performed twice, with either a lipid or a saline infusion; four subjects also had a third test with a glycerol infusion. RESULTS: As shown by similar rates of exogenous glucose appearance, the lipid infusion did not reduce ®rst-pass splanchnic glucose uptake (saline: 1.48 AE 0.18 mmolakga180 min, lipid: 1.69 AE 0.17; glycerol 1.88 AE 0.17; NS), whereas it reduced peripheral glucose uptake by 40% (p`0.01 vs both saline and glycerol infusions). Before oral glucose ingestion, total glucose output was similarily increased by the lipid and glycerol infusions. Total glucose output was signi®cantly increased by FFAs after oral glucose ingestion (saline: 3.68 AE 1.15 mmolakgamin, glycerol: 3.68 AE 1.70, lipid: 7.92 AE 0.88; p`0.0l vs saline and p`0.05 vs glycerol). Glucose cycling rate was about 2.7 mmolakgamin with the three infusions, and tended to decrease all along the lipid infusion, which argues against a stimulation of glucose-6-phosphatase by FFAs. CONCLUSION: In situation of moderate hyperinsulinemia-hyperglycemia, FFAs reduce peripheral, but not splanchnic glucose uptake. Total glucose output is increased by FFAs, by a mechanism that does not appear to involve stimulation of glucose-6-phosphatase. INTRODUCTION: Adipose tissue lipoprotein lipase (LPL) is resistant to acute modulation by insulin in diet-induced obesity, which may contribute to hyperlipidemia. Obesity is also believed to be associated with alterations in nitric oxide (NO) production in several tissues. This study addressed the hypothesis that postprandial resistance of adipose LPL to insulin in dietinduced obese rats is caused by overproduction of NO by inducible NO synthase (iNOS). METHODS: Male Sprague-Dawley rats were fed for 4 weeks with rodent chow or an obesity-promoting high-sucrose, high-fat (HSHF) diet. Food was then removed for 24 h, followed by refeeding for 1 h with rodent chow after a single injection of either saline or aminoguanidine (AGN, 100 mgakg, i.p.), a speci®c iNOS inhibitor. Animals were killed in the fasted state or 1, 3 and 6 h after the onset of refeeding. RESULTS: Postprandial insulinemia peaked at 1 h after the onset of chow refeeding in both the chow-fed and obese HSHF-fed animals and was similar in both cohorts. In chow-fed animals, adipose LPL activity increased $ 60% above fasting 3 h after the onset of refeeding, and AGN was without effect. In untreated rats chronically fed the HSHF diet, adipose LPL did not increase with chow refeeding. However, treatment with AGN increased adipose LPL above levels of untreated rats in the fasted state ( 40%) and postprandially ( 100% at 3 and 6 h).
CONCLUSION:
In adipose tissue of diet-induced obese rats, NO is chronically overproduced through iNOS and results in resistance of adipose LPL to postprandial activation by insulin. Treatment with a speci®c iNOS inhibitor acutely prevents such resistance of adipose LPL to insulin action.
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The in¯uence of insulintherapy on fatty tissue distribution including metabolic control of diabetes B Katra 1 , and J Sieradzki
INTRODUCTION:
The anabolic in¯uence of insulin on tissue is well known. Multicenter control trials have showed that the intensive insulintherapy as a type of treatment of diabetes decreases signi®cantly the risk of late complications. We could suspect that the intensive insulinization could be the reason of central obesity, which is a serious risk factor of coronary heart disease. THE AIM OF THE STUDY: To determine the in¯uence of the insulintherapy to the distribution of fat tissue in the human body. MATERIAL AND METHODS: A prospective study was carried out. 60 subjects with diabetes type 1 and 2 were included into the study; 38 women and 22 men. Each patient was treated with 2 or 4 insulin injections daily. The studied patients were hospitalized in the Clinic for improvement of metabolic control.
Measurements were performed on two occasions: during hospitalization and after approximately 6 months. Metabolic control was assessed based on the HbA1c value and glycemic pro®le. Fatty tissue distribution was determined using dual-energy X-ray absorptiometry (DPX produced by Lunar). The so called``densitometric'' waist-hip-ratio index and visceral fat content were determined. Each person was examined according to late complications. RESULTS: An improvement of glycemic control was observed in 50 subjects (mean HbA1c value at the beginning of the study was: 10.3; in the control measurement: 7.69). There was no improvement of glycemic control in 10 patients. BMI at the beginning and in the end of the study was 27.2 and 27.5 kgam 2 respectively. There was no signi®cant increase of visceral fat content in subjects with the better metabolic control, therefore with larger insulin supply (p 0.44). There was no signi®cance in waist-hip-ratio index. CONCLUSIONS: There is no adverse in¯uence of insulintherapy on fatty tissue distribution. It is well known that metabolic syndrome is associate with visceral adipose tissue (VAT), but several recent studies show stronger association between subcutaneous adipose tissue (SAT) and insulin resistance. Abdominal SAT is divided into two layers by a fascia super®cilais. The purpose of this study is to investigate the clinical signi®cance of deep SAT as a cardiovascular and metabolic risk factors. METHODS: Cross-sectional survey of ®fty-one subjects (2l men and 30 women) who visited obesity clinic in Yeungnam University Hospital. We performed cross-sectional abdominal CT, and we undertook the novel approach of partitioning SAT into the plane super®cial to the fascia within SAT (Super®cial SAT) and within subcutaneous adipose tissue (deep SAT), as well as measurement of VAT. % body fat was measured by bioimpedance analysis (Inbody 2.0, Biospace). Fasting blood samples were analyzed for total cholesterol, HDL-cholesterol, TG, LDL-cholesterol, FFA, insulin, uric acid and glucose. Resting blood pressure was measured. RESULTS: After adjustment of age, sex, smoking, alchol and exercise, deep SAT was proved to be signi®cantly and positively correlated with fasting insulin, FFA, and uric acid (P`0.05). The results was the same in super®cial SAT except for uric acid. VAT was signi®cantly correlated with unfavorable levels of FFA, insulin, HDL-cholesterol, TG and diastolic blood pressure (P`0.05). Moreover, the sum of VAT and deep SAT had a slightly stronger correlation with fasting insulin, FFA than either component considered individually (r 0.45 and 0.41, respectively; both P`0.001). In stepwise multiple regression analysis, deep SAT to be the most powerful of the adiposity measures for explaining the variance in fasting insulin and uric acid levels (r 2 0.20 and 0.27, respectively; both P`0.001; including super®cial SAT, deep SAT, VAT). CONCLUSION: Our results suggest that, the association between deep SAT and fasting insulin, a ®nding which provides further support to the observation that deep SAT may be involved in insulin sensitivity.
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The lipid composition of the diet should not induce the development of obesity INTRODUCTION: It has been suggested that a food intake rich in fat can induce a weight gain independently of the caloric content, because of its low thermogenic cost. Furthermore, it has been hypothesize that fat does not stimulate its own oxidation and, therefore, it would be preferentially stored at the adipose tissue level. METHODS: In this study, three oral loads having the same energy content but a different composition of macronutriments have been administered to a group of obese patients (n 10) compared to lean subjects (n 10). After each load (glucose, cream or mixed), energy expenditure, lipid and glucose oxidations were measured by indirect calorimetry during 8 hours. RESULTS: Glucose thermogenesis is signi®cantly diminished in obese patients (4.4 AE 1.6% vs 10.6 AE 1.2% in controls p`0.001). On the contrary, there is no statistical difference in lipid thermogenesis between obese patients 6.8 AE 1.3% and controls 8.7 AE 1.3%. Lipid oxidation is signi®cantly diminished after both glucose and mixed loads in both obese and control subjects (p`0.001). After the lipid load, the FFA and lipid oxidation are maintained at elevated levels throughout the study in both obese and control subjects. Signi®cant correlations are observed between FFA and lipid oxidation in both control (r 2 0.50; p`0.0001) and obese subjects (r 2 0.49; p`0.000l). CONCLUSION: A speci®c defect in glucose induced thermogenesis is seen in obese patients whereas lipid thermogenesis is not different from controls. Moreover, FFA are able to induce lipid oxidation in both obese and controls. Thus, the lipid composition of the diet should not induce, per se, the development of obesity.
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Effects of orlistat in obese metformin-treated patients with type 2 diabetes: attainment of treatment goals INTRODUCTION: Current type 2 diabetes treatment recommendations of the American Diabetes Association (ADA) emphasise a rigorous approach to diabetes management that includes weight loss when indicated, and aggressive control of glycaemia and cardiovascular risk factors, including hypertension and dyslipidaemia. Achievement of recommended target values for glycaemic control, blood pressure, and lipid levels has been associated with reduced risk of microvascular and macrovascular complications of diabetes. The objective of the present study was to evaluate the extent to which ADA treatment goals were attained in obese patients with type 2 diabetes treated for 1 year in a randomised, double-blind trial of the ef®cacy of a mildly reduced-calorie diet plus orlistat (ORL, n 249), a gastrointestinal lipase inhibitor, or placebo (PL, n 254). METHODS: Overweight and obese adults with a BMI of 28 ± 40 kgam 2 and suboptimal glycaemic control on metformin, alone or combined with other oral agents, participated in this study. RESULTS: At study entry, 100% of the subjects had HbA 1c values greater than the ADA target of`7%; 93.2% exceeded the fasting glucose goal of 5 ± 6.7 mmolaL; 29.3% exceeded the recommended blood pressure of`130a85 mmHg; 74.3% had baseline LDL-C levels b 2.59 mmolaL; 49.2% had triglyceride (TG) levels b 2.258 mmolaL, and 85% of women and 92.1% of men had HDL-C levels`1.42 or`1.16 mmolaL, respectively. After 1 year, ORL lost (mean AE SEM, intention-to-treat population; last observation carried forward) 74.60 AE 0.29% of initial weight vs 71.73 AE 0.25% in PL; p 0.0001. More ORL compared with PL lost ! 5% of initial weight (39.0% vs 15.7%; p`0.0001). The proportion of subjects in each group with baseline values outside of the ADA-recommended goals that achieved the target values after 1 year are shown below (completers population): INTRODUCTION: Orlistat (ORL) enhances weight loss and improves glycaemic control in overweight or obese patients with type 2 diabetes (DM). Metformin (MET) is often used to treat obese patients with DM because, unlike other agents, it produces minimal weight gain. MET is associated with gastrointestinal (GI) effects and ORL has predictable GI effects related to its mechanism of action. The aim of this study was to compare the GI effects observed with concomitant ORL and MET therapy in obese DM to those seen with ORL plus sulphonylurea (SU) therapy. METHODS: A 1-year randomised, double-blind controlled trial (RCT) of a mildly reduced-calorie diet and ORL (120 mg tid) or placebo (PL) was performed in obese DM treated with MET alone or with other oral agents. The incidence of GI events was compared with those observed in a previous RCT of ORL in obese DM treated with SU (Hollander P. Diabetes Care 21:1288, 1998). RESULTS: The total % of patients with at least one GI event was similar in both studies. The % of patients with GI events associated with ORL (ORL minus PL) was also similar with both MET and SU (21% vs 20%). However, the characteristics of the GI events differed between studies. This six months multicenter double blind study included 1004 obese outpatients (18 ± 65 y., BMI 28 ± 40 Kgam 2 ) with comorbidities distributed in 3 groups: hypercholesterolemia (n 197), type 2 diabetes (n 193), hypertension (n 614). Patients were treated with stable doses of speci®c treatments for their diseases for more than 3 months. Patients were randomized to orlistat 120 mg t.i.d. (O) or placebo (P) both combined with a mildly reduced-calorie, reduced-fat diet (mean 1500 Kcaladay). At baseline O and P groups were not signi®cantly different. At 6 months, O patients improved more their weight (75.6 AE 5% vs 71.9 AE 4.2% p`0.001) and waist circumference (75.7 AE 6.9 cm vs 72.7 AE 8.4 cm p`0.001). O and P diabetic patients achieved lower weight loss than non diabetics (see graphs) (p`0.005), but suf®cient to improve better glycaemic control; HBA1c: O: 70.54 AE 1.0% vs P, 70.18 AE 0.9% (p`0.005).
In conclusion, treatment with orlistat combined with a mildly hypocaloric diet induces a clinically relevant weight loss in obese and overweight patients with comorbidities.
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Insulin sensitivity of glycemia and blood ffa as deduced from basal and`O GTT'' data in obese or obese-diabetic subjects In these formulae INSp, GLYp and FFAp insulinemic, glycemic and FFA basal levels or areas during OGTT (75 g glucose, sampling only at 0, 1 and 2 h) of the person studied. Accordingly, we can distinguish ISI-basal and ISI-OGTT. Basal levels and areas are expressed by taking the mean normal value as 1. In normal subjects these Indices are always close to 1, with maximal variations between 0 and 2. RESULTS: Compared to the values in normal subjects (ISI(gly)-OGTT 1.06 AE 0.05 and ISI(ffa)-OGTT 1.08 AE 0.05), in the obese subjects ISI(gly)-OGTT was less reduced than ISI(ffa)-OGTT (values: 0.57 AE 0.04 and 0.47 AE 0.04, respectively), whereas in the obese-diabetic subjects both indices were markedly reduced (values: 0.40 AE 0.03 and 0.41 AE 0.06) (p`0.001 in all instances). Both ISI(gly)-basal and ISI(ffa)-basal were also markedly reduced (p`0.001) in both groups of patients, the former index being less reduced than the later. Multiple regression showed that both indices were inversely correlated with age, BMI, and diastolic blood pressure. CONCLUSION: The observed ®ndings indicate that ISI(gly)-OGTT is less affected in obese than in obese-diabetic patients whereas ISI(ffa)-OGTT is equally reduced in the 2 groups. This might suggest that progression of obesity to diabetes is associated with a fall in the insulin sensitivity of carbohydrate metabolism. The negative correlation of both indices with the diastolic blood pressure appears as noteworthy. In contrast to the``clamp technique'', our indices are simple and are performed under physiological conditions, thus being suitable for clinical or epidemiological studies.
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Age-related increase in visceral fat and change in cardiovascular risks in male obese young adults 
INTRODUCTION:
Visceral adipose tissue, a key factor to the obesity-related health risks, is known to increase with age. In this study, we focused on its agerelated change during early adulthood as well as change in CVD risks. METHODS: In 334 male outpatients of our obesity clinic (age: 18 ± 38 yao), the following parameters were measured: 1) CT scan-assessed abdominal fat areas at the umbilicus, 2) serum lipids (TC, TG) after an overnight fast, and 3) glucose and insulin during GTT. These parameters were crosssectionally compared between three age groups: A: 18 ± 20 yao (n 163), B: 21 ± 26 yao (106), and C: 27 ± 38 yao (65). RESULTS: 1) Although no difference was found in BMI, there was an increase in visceral fat with age. 2) Mean insulin during GTT did not show difference between the groups, but mean glucose was higher in group C. 3) TC and TG showed increase with age. 4) Systolic blood pressure remained unaltered, but diastolic pressure was higher in Group C. (See Table) CONCLUSION: In this population, visceral fat area increases with age and reaches critical level after b 26 yao. Although some parameters remain unchanged throughout these age groups, deterioration in risk pro®le is generally observed after b 26 yao, suggesting the necessity for the early intervention.
Age ( No difference was found in insulin receptor numbers. Negative correlations were found between insulin receptor numbers and plasma insulin levels, the highest being that between high af®nity binding site number and the 2 hour insulin level (r 7 0.76; p`0.001). Fasting leptin correlated with weight (r 0.61, p`0.005) but not with insulin receptor number or af®nity. CONCLUSIONS: These data suggest that the higher insulin resistance observed in obese black than white women may partly be due to a lower insulin binding capacity of the insulin receptor. The negative correlation between receptor number and plasma insulin levels con®rms the phenomenon of receptor down regulation induced by obesity-associated hyperinsulinaemia.
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Relationship between fat free mass and insulin sensitivity in Chinese 
INTRODUCTION:
Recently, several studies focused on the association of fat free mass and insulin resistance. There is so far no report in Chinese. This study was to investigate the relationship between fat free mass and insulin sensitivity in Chinese. METHODS: Glucose metabolism in response to insulin was quantitated by using the euglycemic-hyperinsulinemic clamp (40 mUÂmin 71 Âm 72 ) in combination with 3-[ 3 H] glucose infusion and indirect calorimetry in 9 subjects with BMI`25 kgam 2 and normal glucose tolerance(NW-NGT), 15 subjects with BMI ! 25 kgam 2 and normal glucose tolerance(OB-NGT) and 5 obese subjects with type 2 diabetes(OB-DM). Fat free mass was measured by bioelectrical impedance analysis in all subjects. RESULTS: (1) After adjusted for age, gender and fat mass, the insulinmediated total glucose disposal (glucose disappearance rate, Rd) of both OB-NGT and OB-DM group was lower than that of NW-NGT group. Nonoxidative and oxidative glucose disposal accounted for 55% and 45% of the total glucose disposal respectively in NW-NGT group. Glycogen synthesis was the main intracellular metabolic pathway. (2) Comparing with NW-NGT group, nonoxidative and oxidative glucose disposal decreased 46% and 34% in OB-NGT group, as well as 16% and 35% in OB-DM group respectively.
CONCLUSION:
Besides adipose tissue, skeletal muscle was the primary site of insulin resistance in obese individuals. (1) In OB-NGT group, decreased insulin sensitivity was chie¯y due to impaired glycogen synthesis. (2) In OB-DM group, both defects in glycogen synthesis and oxidative glucose disposal led to decreased insulin sensitivity.
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Gestational diabetes mellitus-a powerful marker of subsequent DM type 2, 15 years after delivery
Obesity unit M 73 Huddinge University Hospital, 141 86 Stockholm, Sweden BACKGROUND: Gestational diabetes mellitus (GDM) complicates 1 ± 3% of all pregnancies and the prevalence is increasing. GDM is a risk factor for diabetes mellitus type 2 later in life, but few long-term studies have addressed this relationship. METHOD: 29 women who were diagnosed with GDM in 1984 ± 85, and a control group (N 46) of women who also delivered children the same year were identi®ed from the Stockholm so-called SPAWN study. They went through a 2-hour glucose tolerance test. Weight and height were measured as well as waist and hip and the women were asked to ®ll in questionnaires about eating and exercise habits.
RESULTS:
The mean age of the GDM and the control group was the same (44.2 years). 34% of the GDM women had been diagnosed with diabetes during follow up, 0% in the control group (p`0.001). BMI (kgam 2 ) for the GDM group which developed overt diabetes type 2 was 28.1 and in the control group 23.1 (p`0.05). Weight gain since ®rst child was 8.4 kg in those who did not got diabetes in the follow up study and 15.1 kg of those how got diabetes. Corresponding weight gain in the control group was 8.1 kg. DISCUSSION: Women who were diagnosed with GDM have a markedly higher risk of developing diabetes mellitus type 2 within 15 years. Overweight and weight increase after delivery seems to predict manifest diabetes mellitus type 2-®ndings, which affect the preventive strategies that need to be developed.
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Tumor necrosis TNFa and insulin resistance in obese women 
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Relationship between hyperinsulinemia, insulin-resistance and arterial blood pressure in extreme obesity Aim of this study was to evaluate the role of several parameters on the development of the metabolic syndrome in severely, class III, obese patients. METHODS: Thirty-two (16 M, 16 F) severely obese patients (BMI ! 40 kgam 2 ) age range 20 ± 65 years, consecutively attending the outpatient obesity clinic, have been selected for the study. An age and sex matched control group (BMI`30 kgam 2 ) was also recruited. Both obese and controls had normal fasting blood glucose, no endocrine disorders, nor were under pharmacological treatments; after an overweight fasting underwent clinical examination, full hematobiochemistry and ECG. RESULTS: In severely obese patients a strong correlation was observed between fasting insulin and serum triglycerides (r 0.824, p`0.001). Insulin-resistance was derived calculating the homeostatic metabolic assessment (HOMA), a population median value of 4.6 for HOMA was used for partitioning the obese patients into 2 groups: group I (low insulin-resistance, HOMA 3.4 AE 0.8), group II (high insulin-resistance, HOMA 9.1 AE 1.6). The two groups, 16 patients each, were comparable for BMI (52 AE 8 vs 56 AE 9, n.s.) and age (40.3 AE 14 vs 41 AE 13, n.s.). Arterial blood pressure (both systolic and diastolic) was signi®cantly higher in group II(126a84 AE 12a7 vs 137a917 AE 14a11, p`0.05) whilst mean blood lipids concentration were substantially low and similar between the two groups (Cholesterol 180 AE 30 vs 182 AE 39 mgadl; HDL-Chol 45.2 AE 10 vs 41.5 AE 11; Triglyceride 114.8 AE 46 vs 142 AE 99). CONCLUSION: These preliminary data suggest that in extremely, class III, normoglycemic obese patients, among the typical parameters of the metabolic syndrome there is a strong relationship between insulin-resistance and blood pressure. BOH was evaluated in day 1,3,7,10,14 (group 1,2) and 1,2 (group3). Metabolic evaluation (glucose, insulin, lipid level, nitrogen balance was performed in the beginning and in the and of the test. Multiple linear regression was used to evaluate the dynamics of BOH. RESULTS: Group 1 and 2-Elevation of BOH is reaching its maximum within several days. The maximum of the VLCD group is about one half of the starvation group. Maximum of BOH level, cumulative area of BOH, the slope of BOH day 1 ± 3, area under the curve of BOH were evaluated using correlation analysis and multiple linear regression. Several regression models were calculated. Group1: normalised BOH sqrt(BOH) 7 0.250 1. 
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Metformin versus diet in overweight diabetic patients
Metformin is considered the ®rst-line drug for overweight diabetics who do not respond to lifestyle modi®cations (diet and exercise habits). We decided to administer metformin in addition to hypocaloric diet to 67 overweight (96.1 AE 16 Kg body-weight b.w.) diabetic patients (41 males, 54.7 AE 8.2 age yrs; 26 females, 53.7 AE 13.6 age yrs), 39 with apparently`1 yr diabetes duration, to search if the antihyperglycaemic metformin effect may be accompanied by a promotion of the weight reduction or stabilization. However, 21 patients declined the drug, preferring to remain on diet only. After one year, all patients lost more than 6 Kg b.w. as a mean, from 96.1 AE 16 to 89.7 AE 13 (p`0.001). More in detail, in the 21 pts only on diet, body weight went from 90.3 AE 13 to 82.6 AE 8.3, p`0.001; Body Mass Index, BMI, from 32.6 AE 6.4 to 29.8 AE 4.3, p`0.004; plasma fasting glucose, FPG, from 166.6 AE 56 to 118.6 AE 30.5 mgadl, p`0.0001; glycated hemoglobin, HbAlc, from 7.9 AE 1.4 to 5.9 AE 1.1, p`0.0001; systolic blood pressure, SBP, from 138.5 AE 20.8 to 130.7 AE 28.8 mmHg, p`0.004; diastolic blood pressure, DBP, from 82.5 AE 12 to 77.3 AE 11.6 mmHg, p`0.0001. In the metformin group (46 pts), b.w. went from 99.2 AE 16.8 to 93.6 AE 13.6 Kg, p`0.0001; BMI, from 35.6 AE 5.6 to 33.7 AE 4.8, p`0.0001; FPG, from 196.1 AE 56.6 to 129.3 AE 30.8 mgadl, p`0.0001; HbAlc, from 8.7 AE 2 to 6.5AE 1.1%, p`0.0001; SBP, from 146.2 AE 15.1 to 136.5 AE 14.5 mmHg, p`0.004; DBP, from 88.9 AE 12.8 to 79.6 AE 9.1 mmHg , p`0.001. No signi®cant difference was observed in terms of metabolic effects and weight decrease between recent-onset and more dated diabetics. Finally, not only for body-weight (p`0.008) and BMI (p`0.013), but even for fasting glucose (p`0.03) and HbAlc (p`0.04) the 1 year ®nal effect seemed in favour of diet treatment instead of metformin. In effect, normalizing post-treatment results for initial patients' body-weight and fasting glucose, the difference dietametformin does disappear. While metformin is a good antihyperglycemic drug in overweight diabetic people, it doesn't add anything to diet in terms of weightreduction.
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DIALOG: diabetes, lifestyle, obesity and genetics: preliminary results DIALOG is a prospective cohort study designed to determine the contribution of lifestyle and genetic variability in lipid metabolism to the development of type 2 diabetes mellitus (DM2) and cardiovascular diseases (CVD). A joint framework of two cohorts was created (the Cohortstudy for Diabetes and Atherosclerosis Maastricht (CoDAM) and the Hoorn Study) in the Netherlands. Part of the baseline measurements in 91 men and 63 women are presented. Subjects were classi®ed as newly diagnosed DM2 or normal glucose tolerant (NGT) by 75 g oral glucose tolerance test according to WHO-criteria (1985) . Height, weight, waist-and hip-circumference, systolic blood pressure (SBP) and sagittal diameter (SAD) were measured. Body mass index and waist-to-hip ratio were calculated. All variables were normally distributed. Both in men and women subjects with newly diagnosed DM2 were older (60.5 AE 6.6 y and 58.8 AE 8.0 y for men; 62.2 AE 6.1 y and 57.8 AE 6.8 y for women). For men, NGT and DM2 differed (p`0.05) in weight (82.1 AE 9.65 kg and 97.2 AE 16.7 kg), BMI (26.6 AE 2.9 kgam 2 and 31.6 AE 5.2 kgam 2 ), waist circumference (93.3 AE 13.7 cm and 110.1 AE 13.1 cm), hip circumference (94.3 AE 13.8 cm and 108.2 AE 11.5 cm), WHR (0.99 AE 0.05 and 1.02 AE 0.05), SAD (200.6 AE 35.6 mm and 251.4 AE 37.7 mm) and SBP (135.8 AE 14.6 mmHg and 156.6 AE 23.2 mmHg). In women, NGT and DM2 signi®cantly differed only in height (163.3 AE 5.4 m and 157.3 AE 6.9 m). Logistic regression analysis showed that SBP and sagittal diameter were strong predictors of DM2 in men, whereas in women height was a strong determinant of DM2. In conclusion risk factors leading to DM2 may differ in men and women.
M Kruijshoop
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Assessing regional myo®ber mass using biolectrical impedance INTRODUCTION: Regional fat distribution is an important determinant of insulin resistance and glucose intolerance. Glucose is to a large extent disposed of in skeletal muscle. Unlike body fat, skeletal muscle remains a dif®cult component to quantify in vivo, particularly the myo®ber component. Myo®bers, or muscle cells, represent muscle contractile elements and their estimation would provide a means of functional measurements. Computed tomography, magnetic resonance imaging, and dual energy X-ray absorptiometry are all capable of providing whole-body and regional skeletal muscle estimates. We tested the hypothesis that regional skeletal muscle mass is highly correlated with electrical resistance, thus potentially providing a simple, practical, and inexpensive means of quantifying skeletal muscle cell mass. METHODS: Multifrequency segmental bioelectrical impedance analysis (Human-DIP, DS, Milan) was used to measure arm resistance while arm myo®ber mass (as potassium) was estimated by regional 40 K counting (NaI rectangular crystals). RESULTS: Subjects were 15 healthy adults (8 females, 7 males, age (X AE SD) 39 AE 2.8 years, BMI 22.9 AE 4.5). Right arm K was 5.23 AE 1.68 g. Arm K was highly correlated with resistance (R 2 0.81, 0.82, and 0.83 for 5 kHz, 50 kHz and 300 kHz, respectively). Multiple regression analyses were done for the development of advanced regional muscle cell mass prediction equations. (Table) CONCLUSION: These results strongly support the hypothesis that appendicular resistance measurements are useful measures of corresponding skeletal muscle cell mass.
Angelo Pietrobelli
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Insulin inhibition on insulin secretion in non diabetic morbidly obese patients: effect of weight loss INTRODUCTION: Insulin inhibition on fasting insulin secretion has been described in normal lean individuals. In addition, this action is blunted in morbidly obese patients and could be related to the insulin resistance. The aim of the present study was to investigate this insulin effect in the morbidly obese, after weight loss induced by vertical banded gastroplasty-gastric bypass (Capella). METHODS: Eight obese patients, normotolerant to glucose, (6Fa2M, BMI 51.8 AE 2.7 kgam 2 , 38AE 4 years, clamp I) and 13 lean controls (8Fa5M, BMI 22.4 AE 0.5 kgam 2 , 33AE 2 years) were submitted to a hyperinsulinemic euglycemic clamp (280 pmolaminam 2 of body surface). The insulin clamp was repeated in the obese patients 3 months (clamp II -weight loss: 719 AE 1% of initial weight), and 14 months after surgery (clamp III -weight loss: 738 AE 1%). C-peptide was used to evaluate the insulin secretion during the clamp (every 20 min intervals from time 720 min to 120 min). RESULTS: The obese, as compared to lean subjects, were insulin resistant (M: 19.1 AE 1.8 vs. 51.7 AE 2.4 mmolamin.kg FFM, p`0.0001) and hyperinsulinemic at fasting state (plasma insulin: 366 AE 137 vs. 86 AE 5 pmolal, p`0.0001) and during an oral glucose tolerance test. The fasting plasma C peptide was higher in the obese group (1258 AE 144 vs. 556 AE 80 pmolal, p`0.0001). The C-peptide decreased less during all the insulin infusion period in the obese patients (mean 60 ± 120 min: 743 AE 6% vs. 711 AE 9% of fasting values, p 0.008). After weight loss, in the obese patients, insulin induced an inhibition on C-peptide secretion similar to lean group (mean 60 ± 120 min: 
INTRODUCTION:
It is known that insulin levels are lower in black than white South African subjects during an oral glucose tolerance test. The aim of this study was to determine whether similar results are obtained using a more physiological test of insulin secretory responsiveness. METHODS: Ten black (OBW) and ten white (OWW) obese (BMI b 30) women were fasted overnight and blood specimens collected. Subjects then drank an emulsion containing 22 g carbohydrate (glucose-sucrose) 12 g protein (casein) and 28 g fat (double cream-olive and sun¯ower oil). Blood samples were collected over a 2 hour period and were analysed for glucose and insulin. The test was repeated on the same subjects but the fat component was left out of the emulsion. RESULTS: No signi®cant differences between ethnic groups or between the two different mixed emulsions were noted for glucose and insulin concentrations at fasting, 1 or 2 hours. However, differences were noted at 30 minutes, as follows (mean AE SEM): 30' insulin (pmolal) 30' glucose (mmolal) 
CONCLUSIONS:
The fat content of the emulsion causes lower blood glucose levels in both ethnic groups probably by slowing down intestinal absorption of glucose. In the OWW this leads to an appropriate decrease in insulin levels but in the OBW insulin levels are the same in both tests. This indicates reduced insulin secretory responsiveness to glucose in OBW and the possibility that fat induces a greater insulin response in OBW than OWW. This may have important consequences for diet and drug treatment of obese black type 2 diabetic patients.
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Effects of different therapeutic methods on the lipid pro®le associated with abdominal obesity OBJECTIVE: The aim of this study was to estimate the in¯uence of mixed hypocaloric diet and metformin on some cardiovascular risk factors in patients with abdominal obesity (without NIDDM). METHODS: Two groups of males (age 25 ± 45, BMI 29 ± 42 kgam 2 ) with abdominal obesity (waist-to-hip circumference ratio (WHR) b 1, waist circumference (WC) b 102 cm were examined before and after the treatment. Plasma levels of total cholesterol (TC) and LDL-cholesterol (LDL-C), triglycerides (TG), HDL-cholesterol (HDL-C); insulinemia, glycemia fasting and after 2 hours OGTT were determined at admission and after 12, 24 weeks of follow up. One group (I)-15 patients received metformin (1000 mg per day) and the diet, the other group (II)-13 patients received only diet. RESULTS: After the treatment: mean BMI decreased by 4.9% (6.6%) and 8.8% (13.65%), weight 4.7% (6.4%) and 9.8% (13.6%), WC -6.96% (6.89%) and 7.8% (11.38%)-in groups I and II after 3 months (6 months), respectively. Lipid levels decreased: TC -16.2% (14%) and 8.4% (14%), LDL-C -21.5% (19%) and 13.12% (19.75%), TG -18.7% (27.6%) and 24.19% (37.9%); fasting insulinemia 17.27% (40.7%) and 7.2% (24.5%), HDL-C increased 1.3% (9%) and 0.1% (3.9%)-in groups I and II after 3 months (6 months), respectively. CONCLUSION: The treatment by metformin and diet is more effective in the management of insulinresistance and some cardiovascular risk factors in patients with abdominal obesity (without NIDDM) after 3 months than diet alone.
The treatment by diet alone results in a similar in lipid pro®le after 6 months period. But at the same time metformin combination with diet is better in reducing insulinresistance, since it signi®cantly decreases fasting insulin level.
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Early onset type 2 diabetes: severe obesity with classical insulin resistance phenotype 
INTRODUCTION:
The relationship between obesity and Type 2 diabetes is well established. Current global trends indicate that the rate of obesity, especially in young adults and children, is increasing dramatically. Consequently, there has been an increase in the incidence of Type 2 diabetes in this population. The purpose of this study was to assess the role of obesity on insulin resistance and insulin secretion in young and middle aged subjects with Type 2 diabetes. METHODS: A total of 10 middle aged subjects with Type 2 diabetes (T2DM) were compared with 4 consecutively diagnosed young (age 25 years) subjects (YT2). All subjects had a 3-hour insulin modi®ed (0.05 Uakg) intravenous glucose tolerance test (0.3 gakg). The minimal model was used to calculate insulin sensitivity (SI) and the acute insulin response to glucose (AIRg). RESULTS: Both groups were obese and had a similar body mass index and waist-to-hip ratio. In addition blood pressure, serum triglycerides, HDL and total cholesterol were similar but LDL was signi®cantly higher in the T2DM group (3.5 AE 0.2 vs. 2.4 AE 0.3 mM, p 0.019). Analysis of the IVGTT indicated that both groups were severely insulin resistant (SI: 0.67 AE 0.14 vs. 0.36 AE 0.20 for the T2DM and YT2, p 0.45). The AIRg was signi®cantly lower in the T2DM group (5.5 AE 1.0 vs. 33.5 AE 8.7, p`0.001) and was inversely correlated with subject age (r 70.84, p 0.0003). CONCLUSION: Obese subjects with Type 2 diabetes have elevated triglycerides and are severely insulin resistant, independent of age or duration of diabetes. In contrast, the pronounced decrease in the ®rst phase insulin response to glucose appears to be independent of obesity. Severe obesity, which is becoming more prevalent in young people, leads to a degree of insulin resistance that causes diabetes by exceeding normal compensatory insulin hypersecretion. 
To assess the in¯uence of both current BMI and preceding BMI changes for the development of abnormal glucose tolerance (AGT) in men without known diabetes. METHODS: Two cohorts originally selected among 380,000 draftees. Drafting age 19.9 y AE 1.9, present age 49.2 y AE 5.7. One group (n 192) was invited from an obese cohort representing all males with juvenile onset obesity (BMI ! 31, mean draft board BMI 33.1 kgam 2 AE 6.1). The other group (n 288) was invited from a control cohort, representing a random sample of 0.5% of all draftees (BMI 21.7kgam 2 AE 2.5). All underwent an OGGT. AGT (de®ned as IGT or diabetes) was classi®ed according to the 1999 WHO criteria. The probability of having AGT was estimated using multiple logistic regression analysis. RESULTS: AGT was diagnosed in 26% of the control subjects and in 46% of the juvenile obese subjects. BMI changes from draft board to present (median and range) were 3. The women of the same weight-related class were comparable for age, weight and BMI, were non-smokers and free from hypertension, diabetes or IGT. They were studied about anthropometry, body composition (BIA), hormonal (including leptin) and lipids levels, and insulin resistance index (HOMA). RESULTS: Compared to pre-OB, post-OB had higher values of two parameters re¯ecting abdominal fat deposition (waist circumference and sagittal diameter, p`0.01), the fat mass and WHR being unchanged. Plasma leptin levels inversely correlated with SHBG (r 2 7 0.18, p`0.0001), were associated with HOMA value (r 2 0.24, p`0.0007) and were higher in post-OB, independently of weight and BMI. SHBG and DHEA-S signi®cantly declined and testosterone increased in post-OB. No differences in cholesterol and LDLcholesterol were found in post-OB versus pre-OB, contrarily to normal weight groups. CONCLUSION: Menopausal status of uncomplicated obese women is associated with a greater abdominal fat deposition, independent of BMI and total fat mass. Minimal changes, if any, occur in lipids and insulin sensitivity, already abnormal before menopause.
P245
Non-diabetic Gypsies are more obese and hyperinsulinemic than Caucasians and fasting plasma glucose concentrations (5.5 AE 0.6 vs. 5.4 AE 0.8 mmola1, p 0.02) than Caucasians. After additional adjustment for BMI and WHR, fasting plasma triglyceride (2.4 AE 2.2 vs. 1.7 AE 1.1 mmolal, p 0.002) and fasting plasma insulin concentrations (9 AE 5 vs. 7 AE 4 mUaml, p 0.0001) were higher in Gypsies than in Caucasians. Cholesterol concentrations and blood pressure did not differ between the ethnic groups. CONCLUSION: We conclude that non-diabetic Gypsies are more obese and have higher plasma insulin and triglyceride levels compared to Caucasians. The high prevalence of type 2 diabetes in the Gypsy population, therefore, may be due to more pronounced obesity and insulin resistance, a hypothesis that needs to be tested in prospective studies.
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Value of simple clinical measures to predict fasting insulin during weight loss and regain 2 ) with no other signi®cant medical history, entered a milk-based low energy weight loss programme for 12 weeks and were then monitored without further intervention up to 52 weeks. Indices of body composition (weight, waist, skinfolds, bioimpedence using Bodystat and Tanita, and a 4 compartment model) and fasting plasma insulin were measured at 0, 12, 24 and 52 weeks. RESULTS: The mean weight change in sequential periods was 79.9 kg (p`0.0001), 0.8 kg (NS) and 4.0 kg (p`0.000l). The table shows F ratios (ANOVA) for the prediction of log fasting plasma insulin concentration at each time point, adjusted for the preceding log insulin conc, and the index of body composition at the start of the measurement period. This analysis shows that use of the 4 compartment model is no better than simple clinical methods of measuring body composition in predicting insulin levels after periods of weight change or during weight stability. Overall, waist performs very well. During periods of weight change, bioimpedence is a stronger predictor of insulin concentration than skinfolds, epecially using Tanita, which may suggest it is more sensitive to changes in abdominal fat than Bodystat. CONCLUSIONS: This study supports the notion that a measure of abdominal fat over total body fat is advantageous in predicting metabolic outcomes in moderately overweight women.
JD Krebs
Methods
carbohydrate from white bread on eight test days. Venous blood samples were taken before, and every 30 minutes for three hours after test meals. Each test meal was repeated four times by each subject in random order. Each subject consumed the same pretest meal on the previous night. RESULTS: The mean coef®cient of variation after bread varied from 11.6% at 90 minutes to 16.1% at 30 minutes, whereas the mean coef®cient of variation after glucose varied from 9.6% at 90 minutes to 14.5% at 0 minutes. No signi®cant differences were found at any time point between test meals in intra-individual variation. However, the mean coef®cient of variation of the incremental area under the curve (from baseline) (IAUC) was 27.9% after bread, compared to 11.6% after glucose. The mean coef®cient of variation of the total area under the curve (from zero) after bread was 10.6%, compared to 10.0% after glucose. CONCLUSION: These results suggest that Type 2 diabetic subjects only showed signi®cant intra-individual variation in blood glucose response to the two test meals with respect to the IAUC. Inter-individual variation in blood glucose response between glucose and white bread showed no signi®cant difference. Vuk Vrhovac University Clinic, Dugi dol 4a, Zagreb, Croatia
Obesity as a risk factor is associated with the development of various diseases (diabetes mellitus, impaired glucose tolerance, cholelithiasis, arterial hypertension, colon cancer etc.). Two hundred and nine patients, 107 women and 98 men, aged 20 ± 67 yrs. with BMI 29 ± 40 were during a ®ve-year period (1995 ± 1999) referred to the Metabolic Department of the Vuk Vrhovac University Clinic for obesity. Clinical examination and laboratory tests performed at their arrival detected other risk factors for the development of atherosclerosis (impaired glucose tolerance, diabetes mellitus, arterial hypertension, hyperlipoproteinemia).
The analysis of checkups performed during that period showed that 138 patients (66.03%), after receiving recommendations for body weight reduction and treatment of other risk factors, did not return to our out-patient unit. The remaining patients (71, i.e. 33.97%) continued to arrive for their control weight measurements and metabolic checkups. The analysis of the distribution of risk factors showed that the rate of patients with two or three risk factors who continued arriving for regular checkups was signi®cantly higher (45.07%) than in the control group (30.43%). The percentage of patients with only one risk factor who continued arriving for regular checkups (36.62%) did not signi®cantly differ from the percentage of those who did not return to our department at all (39.13%). The percentage of patients with no other risk factors was in the followed group signi®cantly lower (18.31%) than in the control group (30.43%). Further analysis of the followed group of obese patients (N 71) revealed the largest percentage of those with lipid metabolism disorder (26.76%), hyperlipoproteinemia and arterial hypertension (16.90%), hyperlipoproteinemia and glucose metabolism disorders, i.e. impaired glucose tolerance and diabetes mellitus (9.86%), arterial hypertension and glucose metabolism impairment (9.86%) and a combination of all these risk factors (8.46%).
The follow-up of the regularity of checkups showed that the presence of risk factors whose effect in the atherogenesis process can be signi®cantly reduced by body weight reduction had a key role in the motivation of patients to lose weight.
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Waist circumference and abdominal sagital diameter as predictors of lipid abnormalities in adults During the last decade there was enough scienti®cal proves suggesting that abdominal fat depoes can be one of the most important factors in metabolic disturbances associated with overweight. The aim of this study was to show the relationship of simple anthropometric measures: waist circumference and abdominal sagital diameter and levels of serum lipids in adult population.
Participants were 788 female and 313 male patients admitted in Department of Nutrition for dietetic counsel with no history of previously known chronic disease. The age of the patients ranged from 21 to 70. Body height and weight were measured with standard anthropometer and from this data we calculated body mass index (BMI 
INTRODUCTION:
The rising prevalence of type 2 diabetes can largely be attributed to the increasing frequency of overweight and obesity in the population. However, in spite of health professional's awareness of the relationship between obesity and type 2 diabetes it is clear that many obese patients remain undiagnosed. We examined the incidence of undiagnosed diabetes in patients referred to a hospital clinic for the management of those with morbid obesity. METHODS: All patients referred to the hospital obesity clinic attended for assessment prior to their ®rst clinic visit. A fasting venous blood sample was taken on which plasma glucose was measured. Those already known to have diabetes were not included in the further analysis. Those patients found to have a fasting plasma glucose above 6 mmolaL underwent a 75 g oral glucose tolerance test. Information on a family history of diabetes was also obtained. RESULTS: 84 patients (66 women) attended for a fasting venous plasma glucose. 5 out of 18 men (28%) had a plasma glucose of b 7.8 mmolaL (mean 11.6 AE 1.7 mmolaL) with a mean HbA1c of 8.8 AE 0.7% (normal`6.7%). 6 women had a fasting glucose between 6 and 7 mmolaL and went on to have an oral glucose tolerance test. In 1 case the glucose tolerance test was diagnostic of diabetes, whilst the other 5 women had impaired glucose tolerance. Those subjects with impaired glucose tolerance or diabetes were older than those without (51.4 AE 2.9 y vs 40.5 AE 1.5 y; p 0.007), but were not signi®cantly more obese (BMI 53.4 AE 2.7 vs 48.4 AE 1.2 kg m 72 ) and nor did waist hip ratio differ between the groups. 4 of the 11 patients with impaired glucose tolerance and diabetes had a ®rst degree relative with type 2 diabetes. CONCLUSION: Patients with morbid obesity have a high prevalence of undiagnosed diabetes and impaired glucose tolerance. These patients are easy to identify for screening within primary care and should have a fasting glucose measured, particularly those over 40 years of age and those with a family history of type 2 diabetes.
